MiRNA153 Reduces Effects of Chemotherapeutic Agents or Small Molecular Kinase Inhibitor in HCC Cells

被引:52
作者
Chen, Yan [1 ,3 ]
Feng, Fan [2 ]
Gao, Xudong [1 ]
Wang, Chunping [1 ]
Sun, Huiwei [1 ]
Zhang, Cuihong [1 ]
Zeng, Zhen [1 ]
Lu, Yinying [1 ]
An, Linjing [1 ]
Qu, Jianhui [1 ]
Wang, Fusheng [3 ]
Yang, Yongping [1 ]
机构
[1] Med Sch Chinese PLA, Beijing Hosp 302, Ctr Therapeut Res Hepatocellular Carcinoma, Beijing 100039, Peoples R China
[2] Gen Hosp Shenyang Mil Command, Dept Pharm, Shenyang 110016, Peoples R China
[3] Med Sch Chinese PLA, Beijing Hosp 302, Inst Translat Hepatol, Res Ctr Biol Therapy, Beijing 100039, Peoples R China
关键词
Etoposide; HCC cells; miR-153; PTEN; paclitaxel; sorafenib; LINE-1 ORF-1P FUNCTIONS; HEPATOCELLULAR-CARCINOMA; TRASTUZUMAB RESISTANCE; CANCER; PROMOTES; PROLIFERATION; PROGRESSION; ACTIVATION; TARGETS; AKT;
D O I
10.2174/1568009615666150225122635
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
MicroRNA-153 (miR-153) is considered to be a tumor regulator. Silencing of miR-153 expression induced apoptosis in breast cancer cells. Data on mechanism suggest that up-regulation of miR-153 level promotes cell proliferation via the down regulation of the expression of PTEN or FOXO1, which attenuates the proliferation of cancerous cells. This study aims to identify the effect of miR-153 on the activity of chemotherapeutic and targeted agents in HCC cells and to investigate the mechanisms involved. MTT, soft agar, trans-well and flow cytometry assays were performed to examine whether miR-153 down-regulated the activity of the chemotherapeutic and targeted drugs, Sorafenib, Etoposide and Paclitaxel in HCC cells. The rate of proliferation inhibition, relative survival rates and IC50 values of each drug were calculated. Western blot and luciferase assays were performed to assess whether miR-153 modulates the expression of important genes related to cell proliferation, apoptosis or survival. Results showed that miR-153 attenuated the effect of Etoposide, Paclitaxel and Sorafenib on HepG2 cells; the IC50 value increased from 0.25 +/- 0.01 mu mol/L to 1.02 +/- 0.14 mu mol/L, 0.05 +/- 0.01 mu mol/L to 0.14 +/- 0.02 mu mol/L and from 1.09 +/- 0.15 mu mol/L to 5.18 +/- 0.99 mu mol/L, respectively. In addition, miR-153 also reduced the effect of these drugs on MHCC-97H, MHCC-97 L and L-02 cells; and it also reduced the effects of Sorafenib, Etoposide and Paclitaxel on anchorindependent growth of HepG2 cells. Over-expression of miR-153 down-regulated the activity of Etoposide and Paclitaxel on cell cycle arrest of HepG2 cells and the effect of Sorafenib on the invasion and migration of HepG2 cells. Furthermore, overexpression of miR-153 also enhanced the growth of HepG2, MHCC-97H, MHCC-97 L and L-02 cells. Mechanisms data showed that overexpression of miR-153 down regulated the activity of luciferase reporters, p15-Luc and p21-Luc; and enhanced the protein level of pro-survival or anti-apoptosis proteins Survivin and BCL-2. These results show that overexpression of miR-153 protects HepG2 cells against the effects of these drugs via multiple mechanisms, and miR-153 may be a novel target for HCC in future diagnostic and therapeutic interventions.
引用
收藏
页码:176 / 187
页数:12
相关论文
共 46 条
  • [1] miR-153 Silencing Induces Apoptosis in the MDA-MB-231 Breast Cancer Cell Line
    Anaya-Ruiz, Maricruz
    Cebada, Jorge
    Delgado-Lopez, Guadalupe
    Luisa Sanchez-Vazquez, Maria
    Martin Perez-Santos, Jose Luis
    [J]. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2013, 14 (05) : 2983 - 2986
  • [2] [Anonymous], 2014, Mol Neurobiol
  • [3] [Anonymous], J MED FOOD
  • [4] Management of hepatoceullular carcinoma
    Bruix, J
    Sherman, M
    [J]. HEPATOLOGY, 2005, 42 (05) : 1208 - 1236
  • [5] Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model
    Cao, Mengde
    Xu, Yiling
    Youn, Je-in
    Cabrera, Roniel
    Zhang, Xiaokui
    Gabrilovich, Dmitry
    Nelson, David R.
    Liu, Chen
    [J]. LABORATORY INVESTIGATION, 2011, 91 (04) : 598 - 608
  • [6] Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
    Cheng, Ann-Lii
    Kang, Yoon-Koo
    Chen, Zhendong
    Tsao, Chao-Jung
    Qin, Shukui
    Kim, Jun Suk
    Luo, Rongcheng
    Feng, Jifeng
    Ye, Shenglong
    Yang, Tsai-Sheng
    Xu, Jianming
    Sun, Yan
    Liang, Houjie
    Liu, Jiwei
    Wang, Jiejun
    Tak, Won Young
    Pan, Hongming
    Burock, Karin
    Zou, Jessie
    Voliotis, Dimitris
    Guan, Zhongzhen
    [J]. LANCET ONCOLOGY, 2009, 10 (01) : 25 - 34
  • [7] Proto-oncogene FBI-1 Represses Transcription of p21CIP1 by Inhibition of Transcription Activation by p53 and Sp1
    Choi, Won-Il
    Jeon, Bu-Nam
    Yun, Chae-Ok
    Kim, Pyung-Hwan
    Kim, Sung-Eun
    Choi, Kang-Yell
    Kim, Se Hoon
    Hur, Man-Wook
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (19) : 12633 - 12644
  • [8] Eukaryotic Translation Initiator Protein 1A Isoform, CCS-3, Enhances the Transcriptional Repression of p21CIP1 by Proto-oncogene FBI-1 (Pokemon/ZBTB7A)
    Choi, Won-Il
    Kim, Youngsoo
    Kim, Yuri
    Yu, Mi-Young
    Park, Jungeun
    Lee, Choong-Eun
    Jeon, Bu-Nam
    Koh, Dong-In
    Hur, Man-Wook
    [J]. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2009, 23 (4-6) : 359 - 370
  • [9] MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies
    Choudhary, G. S.
    Al-Harbi, S.
    Mazumder, S.
    Hill, B. T.
    Smith, M. R.
    Bodo, J.
    Hsi, E. D.
    Almasan, A.
    [J]. CELL DEATH & DISEASE, 2015, 6 : e1593 - e1593
  • [10] Celecoxib suppresses hepatoma stemness and progression by up-regulating PTEN
    Chu, Tian-Huei
    Chan, Hoi-Hung
    Kuo, Hsiao-Mei
    Liu, Li-Fen
    Hu, Tsung-Hui
    Sun, Cheuk-Kwan
    Kung, Mei-Lang
    Lin, Shih-Wei
    Wang, E-Ming
    Ma, Yi-Ling
    Cheng, Kwan-Hung
    Lai, Kwok Hung
    Wen, Zhi-Hong
    Hsu, Ping-I
    Tai, Ming-Hong
    [J]. ONCOTARGET, 2014, 5 (06) : 1475 - 1490